StreetInsider.com News Articles

ProMIS Neurosciences (PMN) PT Raised to $33 at Chardan

Tue, 28 Jul 2026 10:15:15 -0400

Chardan analyst Keay Nakae raised the price target on ProMIS Neurosciences (NASDAQ: PMN) to $33.00 (from $20.00) while maintaining a Buy rating.

The analyst comments "PMN (Buy): Increasing PT to $33 On Encouraging Interim Phase Ib Data. ProMIS Neurosciences has reported positive blinded interim safety and biomarker data at 6-months from the PRECISE-AD phase 1b study evaluating PMN310 in Alzheimer s disease (AD). We believe that this data provides important poof of mechanism that ProMIS' lead mAb asset, PMN-310, is acting as designed. PMN-310 specifically targets soluble toxic Amyloid-β oligomers (AβOs), as they are believed to be highly toxic to neurons,

ProMIS Neurosciences (PMN) PT Raised to $33 at Chardan

Tue, 28 Jul 2026 10:15:15 -0400

Chardan analyst Keay Nakae raised the price target on ProMIS Neurosciences (NASDAQ: PMN) to $33.00 (from $20.00) while maintaining a Buy rating.

Form 8-K ProMIS Neurosciences For: Jul 28

Tue, 28 Jul 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260728/26821721.html

Form 8-K ProMIS Neurosciences For: Jul 28

Tue, 28 Jul 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260728/26821721.html

ProMIS reports no ARIA-E in interim Alzheimer's drug trial data

Tue, 28 Jul 2026 06:00:15 -0400

ProMIS Neurosciences Inc. (Nasdaq: PMN) reported blinded six-month interim safety and biomarker results from its PRECISE-AD Phase 1b trial evaluating PMN310, a drug candidate for mild Alzheimer's disease and mild cognitive impairment due to Alzheimer's disease.

In the interim analysis covering 136 patients, no cases of amyloid-related imaging abnormalities-edema (ARIA-E) were observed across any genotype. Total ARIA incidence was 4.4%, consisting solely of microhemorrhages (ARIA-H), all of which were mild and asymptomatic. No treatment-related serious adverse events or drug-related discontinuations were reported.

The trial population included 61% APOE4 carriers, of which 11% were homozygotes. No ARIA-E was observed in any of these

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial

Tue, 28 Jul 2026 06:00:00 -0400

No ARIA-E observed across all genotypes, including APOE4 homozygotes

ARIA-H tracking background rates

Early biomarker movement consistent with target engagement

12-month topline results expected in Q1 2027

Cambridge, Massachusetts, July 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biopharmaceutical company developing therapeutics that selectively target toxic misfolded proteins in neurodegenerative diseases, today announced positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Phase 1b trial of its

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial

Tue, 28 Jul 2026 06:00:00 -0400

No ARIA-E observed across all genotypes, including APOE4 homozygotes

ARIA-H tracking background rates

Early biomarker movement consistent with target engagement

12-month topline results expected in Q1 2027

ProMIS to host webinar on Alzheimer's drug trial interim data

Mon, 27 Jul 2026 16:00:09 -0400

ProMIS Neurosciences Inc. (Nasdaq: PMN) announced it will host a webinar on July 28, 2026, to discuss six-month blinded interim data from its PRECISE-AD Phase 1b clinical trial evaluating PMN310 in patients with early Alzheimer's disease.

The one-hour webinar, scheduled for 8:00 a.m. ET, will feature ProMIS Chief Executive Officer Neil Warma and Chief Medical Officer Dr. Larry Altstiel, alongside two outside specialists: Dr. Will Mantyh, Associate Professor at the University of Minnesota Medical School, and Dr. Michael Weiner, Professor Emeritus at the University of California, San Francisco.

The discussion will focus on blinded aggregate safety data and overall trends in select

ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease

Mon, 27 Jul 2026 16:00:00 -0400

Cambridge, Massachusetts, July 27, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will host a webinar on Tuesday, July 28, 2026, at 8:00 am ET, featuring Key Opinion Leaders (KOLs) Dr. Will Mantyh, Associate Professor with Tenure, University of Minnesota Medical School and Dr. Michael Weiner, Professor Emeritus, University of California, San Francisco. They will join company leadership to discuss the Company's six-month blinded interim data from the PRECISE-AD Phase 1b trial evaluating PMN310 in patients

ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease

Mon, 27 Jul 2026 16:00:00 -0400

Chardan Starts ProMIS Neurosciences (PMN) at Buy

Mon, 27 Jul 2026 02:53:32 -0400

Chardan analyst Keay Nakae initiates coverage on ProMIS Neurosciences (NASDAQ: PMN) with a Buy rating and a price target of $20.00.

The analyst comments: “ProMIS' lead asset, PMN-310, is targeting Alzheimer's Disease (AD), a disease for which the competitive landscape is evolving. PMN-310 specifically targets toxic Amyloid-β oligomers (AβOs), while avoiding binding to Aβ plaque which can result in ARIA (MRI findings of swelling and bleeding of the brain), and monomer binding which reduces the available mAb for target saturation. Hence, while Aβ is currently the most validated target for AD, with multiple approved disease-modifying therapies, mAbs which only target the

Chardan Starts ProMIS Neurosciences (PMN) at Buy

Mon, 27 Jul 2026 02:53:32 -0400

Chardan analyst Keay Nakae initiates coverage on ProMIS Neurosciences (NASDAQ: PMN) with a Buy rating and a price target of $20.00.

H.C. Wainwright Reiterates Buy Rating on ProMIS Neurosciences (PMN)

Wed, 15 Jul 2026 07:41:24 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $18.00 price target on ProMIS Neurosciences (NASDAQ: PMN).

The analyst commented: "ProMIS Neurosciences yesterday announced the first human evidence of dose-dependent amyloid-beta oligomer (AβO) reduction by its lead Alzheimer’s disease (AD) drug candidate, PMN310, presented at AAIC 2026 in London, UK. The findings, drawn from analysis of samples collected during the company's Phase 1a trial in healthy volunteers, demonstrated that individuals receiving PMN310 exhibited a dose-dependent reduction in detectable AβO in cerebrospinal fluid (CSF) at both three and 29 days after dosing. While healthy individuals carry lower oligomer burdens than AD

ProMIS reports human evidence of PMN310 reducing amyloid-beta oligomers

Tue, 14 Jul 2026 05:50:13 -0400

ProMIS Neurosciences Inc. (Nasdaq: PMN) presented data at the 2026 Alzheimer's Association International Conference showing that its lead drug candidate, PMN310, produced a dose-dependent reduction of amyloid-beta oligomers (AβO) in human cerebrospinal fluid following a single dose in healthy volunteers.

The findings come from analysis of samples collected during the company's Phase 1a trial (NCT06105528). Participants receiving PMN310 showed reduced detectable AβO levels in cerebrospinal fluid at both three and 29 days after dosing. The company described this as one of the first quantitative demonstrations of treatment-related oligomer reduction in humans.

The oligomer measurements were conducted using surface-based fluorescence intensity distribution analysis

ProMIS reports human evidence of PMN310 reducing amyloid-beta oligomers

Tue, 14 Jul 2026 05:50:13 -0400

The oligomer measurements were conducted using surface-based fluorescence intensity distribution analysis

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

Tue, 14 Jul 2026 02:30:00 -0400

PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers

Represents one of the first quantitative measures of treatment-related effects on oligomer levels in a clinical trial

Company on track to present six-month blinded interim data from its Phase 1b trial in the coming weeks

Poster to be presented today, July 14, at the 2026 Alzheimer’s Association International Conference® (AAIC)

Cambridge, Massachusetts, July 14, 2026 (GLOBE NEWSWIRE) --

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

Tue, 14 Jul 2026 02:30:00 -0400

PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers

Represents one of the first quantitative measures of treatment-related effects on oligomer levels in a clinical trial

Company on track to present six-month blinded interim data from its Phase 1b trial in the coming weeks

Poster to be presented today, July 14, at the 2026 Alzheimer’s Association International Conference® (AAIC)

Cambridge, Massachusetts, July 14, 2026 (GLOBE NEWSWIRE) --

Roth/MKM Starts ProMIS Neurosciences (PMN) at Buy

Tue, 07 Jul 2026 16:12:53 -0400

Roth/MKM analyst Boobalan Pachaiyappan initiates coverage on ProMIS Neurosciences (NASDAQ: PMN) with a Buy rating and a price target of $19.00.
For an analyst ratings summary and ratings history on ProMIS Neurosciences click here. For more ratings news on ProMIS Neurosciences click here.
Shares of ProMIS Neurosciences closed at $13.71 yesterday.

Cantor Fitzgerald Starts ProMIS Neurosciences (PMN) at Overweight

Mon, 29 Jun 2026 16:44:58 -0400

Cantor Fitzgerald analyst Pete Stavropoulos initiates coverage on ProMIS Neurosciences (NASDAQ: PMN) with a Overweight rating.
For an analyst ratings summary and ratings history on ProMIS Neurosciences click here. For more ratings news on ProMIS Neurosciences click here.
Shares of ProMIS Neurosciences closed at $10.53 yesterday.

H.C. Wainwright Reiterates Buy Rating on ProMIS Neurosciences (PMN)

Wed, 24 Jun 2026 06:47:04 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $18.00 price target on ProMIS Neurosciences (NASDAQ: PMN).
The analyst commented: "We recently hosted a corporate presentation by ProMIS Neurosciences management at our 7th Annual H.C. Wainwright & Co. Neuro Perspectives Conference. During the presentation, the company disclosed that it is planning to develop a subcutaneous formulation of PMN310, which we believe could provide a key convenience advantage vs. existing anti-amyloid antibodies—these agents all must be administered intravenously. Preparation is already underway for a single registrational Phase 3 study of PMN310, pending positive Phase 1b results. Preclinical advancement of amyotrophic lateral

H.C. Wainwright Reiterates Buy Rating on ProMIS Neurosciences (PMN)

Tue, 09 Jun 2026 06:48:11 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $18.00 price target on ProMIS Neurosciences (NASDAQ: PMN).
The analyst commented: "We remind investors that the company’s ongoing Phase 1b trial, PRECISE-AD, reached full enrollment in December 2025—exceeding the company’s target of 128 subjects with a total of 144 patients enrolled—and is now approaching the six-month time point. The upcoming blinded interim data analysis anticipated early in 3Q26 (i.e., next quarter, or within the coming weeks) will summarize aggregate safety data and overall trends in key biomarkers across all study participants, without revealing treatment assignments. Since the analysis pools active and

Form S-8 ProMIS Neurosciences

Fri, 29 May 2026 16:17:00 -0400
si-local-file:///var/storage/secattach/20260529/26575404.html

Form S-8 ProMIS Neurosciences

Fri, 29 May 2026 16:17:00 -0400
si-local-file:///var/storage/secattach/20260529/26575404.html

ProMIS Neurosciences to Participate in Upcoming Conferences in June

Thu, 28 May 2026 10:13:00 -0400

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming June 2026 conferences, and will be available for one-on-one meetings.

Conference details below:

Jefferies Global Healthcare Conference, June 2-4, 2026
Location: New York, NY
Presentation: Thursday, June 4, 2026, from 11:40 a.m. to 12:10 p.m. ET
Webcast link: Click here.

Virtual Alzheimer’s R&D Day, organized by Wolfe Research, June 4, 2026
Presentation: Thursday, June 4, 2026, from

ProMIS Neurosciences to Participate in Upcoming Conferences in June

Thu, 28 May 2026 10:13:00 -0400

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming June 2026 conferences, and will be available for one-on-one meetings.

Conference details below:

Jefferies Global Healthcare Conference, June 2-4, 2026
Location: New York, NY
Presentation: Thursday, June 4, 2026, from 11:40 a.m. to 12:10 p.m. ET
Webcast link: Click here.

Virtual Alzheimer’s R&D Day, organized by Wolfe Research, June 4, 2026
Presentation: Thursday, June 4, 2026, from